{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:14:57Z","timestamp":1768778097568,"version":"3.49.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CSIR-Institute of Microbial Technology","award":["OLP0501"],"award-info":[{"award-number":["OLP0501"]}]},{"name":"CSIR-Institute of Microbial Technology","award":["OLP0143"],"award-info":[{"award-number":["OLP0143"]}]},{"name":"CSIR-Institute of Microbial Technology","award":["MLP0024"],"award-info":[{"award-number":["MLP0024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Viruses are responsible for causing various epidemics and pandemics with a high mortality rate e.g. ongoing SARS-CoronaVirus-2 crisis. The discovery of novel antivirals remains a challenge but drug repurposing is emerging as a potential solution to develop antivirals in a cost-effective manner. In this regard, we collated the information of repurposed drugs tested for antiviral activity from literature and presented it in the form of a user-friendly web server named \u2018DrugRepV\u2019. The database contains 8485 entries (3448 unique) with biological, chemical, clinical and structural information of 23 viruses responsible to cause epidemics\/pandemics. The database harbors browse and search options to explore the repurposed drug entries. The data can be explored by some important fields like drugs, viruses, drug targets, clinical trials, assays, etc. For summarizing the data, we provide overall statistics of the repurposed candidates. To make the database more informative, it is hyperlinked to various external repositories like DrugBank, PubChem, NCBI-Taxonomy, Clinicaltrials.gov, World Health Organization and many more. \u2018DrugRepV\u2019 database (https:\/\/bioinfo.imtech.res.in\/manojk\/drugrepv\/) would be highly useful to the research community working to develop antivirals.<\/jats:p>","DOI":"10.1093\/bib\/bbaa421","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T12:13:05Z","timestamp":1608639185000},"page":"1076-1084","source":"Crossref","is-referenced-by-count":21,"title":["DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses"],"prefix":"10.1093","volume":"22","author":[{"given":"Akanksha","family":"Rajput","sequence":"first","affiliation":[{"name":"Virology Unit and Bioinformatics Centre, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39A, Chandigarh-160036, India"}]},{"given":"Archit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Virology Unit and Bioinformatics Centre, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39A, Chandigarh-160036, India"}]},{"given":"Kirti","family":"Megha","sequence":"additional","affiliation":[{"name":"Virology Unit and Bioinformatics Centre, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39A, Chandigarh-160036, India"}]},{"given":"Anamika","family":"Thakur","sequence":"additional","affiliation":[{"name":"Virology Unit and Bioinformatics Centre, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39A, Chandigarh-160036, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Virology Unit and Bioinformatics Centre, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39A, Chandigarh-160036, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India"}]}],"member":"286","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"2021032314375369700_ref1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/095632020501600302","article-title":"Achievements and challenges in antiviral drug discovery","volume":"16","author":"Littler","year":"2005","journal-title":"Antivir Chem Chemother"},{"key":"2021032314375369700_ref2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1073\/pnas.58.1.134","article-title":"Poxvirus DNA-dependent RNA polymerase","volume":"58","author":"Kates","year":"1967","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021032314375369700_ref3","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vew014","article-title":"Antiviral drug resistance as an adaptive process","volume":"2","author":"Irwin","year":"2016","journal-title":"Virus Evol"},{"key":"2021032314375369700_ref4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2021032314375369700_ref5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug repurposing for viral infectious diseases: how far are we?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol"},{"key":"2021032314375369700_ref6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2021032314375369700_ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2021032314375369700_ref8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM198702263160925","article-title":"Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report","volume":"316","author":"Yarchoan","year":"1987","journal-title":"N Engl J Med"},{"key":"2021032314375369700_ref9","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"2021032314375369700_ref10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-020-00933-4","article-title":"Chloroquine for COVID-19 infection","volume":"43","author":"Moore","year":"2020","journal-title":"Drug Saf"},{"key":"2021032314375369700_ref11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antiviral Res"},{"key":"2021032314375369700_ref12","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021032314375369700_ref13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/infdis\/jiu377","article-title":"Repurposing of prochlorperazine for use against dengue virus infection","volume":"211","author":"Simanjuntak","year":"2015","journal-title":"J Infect Dis"},{"key":"2021032314375369700_ref14","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2017.29","article-title":"A standard database for drug repositioning","volume":"4","author":"Brown","year":"2017","journal-title":"Sci Data"},{"key":"2021032314375369700_ref15","doi-asserted-by":"crossref","first-page":"D1060","DOI":"10.1093\/nar\/gkq1037","article-title":"PROMISCUOUS: a database for network-based drug-repositioning","volume":"39","author":"Eichborn","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2021032314375369700_ref16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrd4619","article-title":"Anticancer drugs: advancing precision medicine in silico","volume":"14","author":"","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2021032314375369700_ref17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.drudis.2016.09.019","article-title":"Design of efficient computational workflows for in silico drug repurposing","volume":"22","author":"Vanhaelen","year":"2017","journal-title":"Drug Discov Today"},{"key":"2021032314375369700_ref18","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24234373","article-title":"A repurposing approach for uncovering the anti-tubercular activity of FDA-approved drugs with potential multi-targeting profiles","volume":"24","author":"Battah","year":"2019","journal-title":"Molecules"},{"key":"2021032314375369700_ref19","doi-asserted-by":"crossref","first-page":"D894","DOI":"10.1093\/nar\/gkx1157","article-title":"aBiofilm: a resource of anti-biofilm agents and their potential implications in targeting antibiotic drug resistance","volume":"46","author":"Rajput","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2021032314375369700_ref20","doi-asserted-by":"crossref","first-page":"W199","DOI":"10.1093\/nar\/gks450","article-title":"AVPpred: collection and prediction of highly effective antiviral peptides","volume":"40","author":"Thakur","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2021032314375369700_ref21","doi-asserted-by":"crossref","first-page":"D634","DOI":"10.1093\/nar\/gkv1076","article-title":"SigMol: repertoire of quorum sensing signaling molecules in prokaryotes","volume":"44","author":"Rajput","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2021032314375369700_ref22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120066","article-title":"Prediction and analysis of quorum sensing peptides based on sequence features","volume":"10","author":"Rajput","year":"2015","journal-title":"PLoS One"},{"key":"2021032314375369700_ref23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01389-18","article-title":"Beyond members of the family, sofosbuvir also inhibits chikungunya virus replication","volume":"63","author":"Ferreira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021032314375369700_ref24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2003.11.006","article-title":"A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus","volume":"62","author":"Paragas","year":"2004","journal-title":"Antiviral Res"},{"key":"2021032314375369700_ref25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7883\/yoken.67.209","article-title":"Development of a novel Dengue-1 virus replicon system expressing secretory Gaussia luciferase for analysis of viral replication and discovery of antiviral drugs","volume":"67","author":"Kato","year":"2014","journal-title":"Jpn J Infect Dis"},{"key":"2021032314375369700_ref26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003095","article-title":"High content image-based screening of a protease inhibitor library reveals compounds broadly active against Rift Valley fever virus and other highly pathogenic RNA viruses","volume":"8","author":"Mudhasani","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2021032314375369700_ref27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J Infect"},{"key":"2021032314375369700_ref28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/cpt.1909","article-title":"Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics","volume":"108","author":"Arshad","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2021032314375369700_ref29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jviromet.2005.05.010","article-title":"Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus","volume":"129","author":"Ivens","year":"2005","journal-title":"J Virol Methods"},{"key":"2021032314375369700_ref30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004695","article-title":"The viral polymerase inhibitor 7-Deaza-2\u2019-C-Methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model","volume":"10","author":"Zmurko","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2021032314375369700_ref31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hfor the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021032314375369700_ref32","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"Wilde","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021032314375369700_ref33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect Dis"},{"key":"2021032314375369700_ref34","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1021\/acs.jnatprod.5b00073","article-title":"Antiviral activity of diterpene esters on chikungunya virus and HIV replication","volume":"78","author":"Nothias-Scaglia","year":"2015","journal-title":"J Nat Prod"},{"key":"2021032314375369700_ref35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"Madelain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021032314375369700_ref36","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acsinfecdis.0c00343","article-title":"Old drugs for a new virus: repurposed approaches for combating COVID-19","volume":"6","author":"Saul","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2021032314375369700_ref37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-25780-3","article-title":"Favipiravir (T-705) protects against Nipah virus infection in the hamster model","volume":"8","author":"Dawes","year":"2018","journal-title":"Sci Rep"},{"key":"2021032314375369700_ref38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"2021032314375369700_ref39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-3542(02)00013-X","article-title":"Identification of active antiviral compounds against a New York isolate of West Nile virus","volume":"55","author":"Morrey","year":"2002","journal-title":"Antiviral Res"},{"key":"2021032314375369700_ref40","article-title":"Identification of vaccinia virus inhibitors and cellular functions necessary for efficient viral replication by screening bioactives and FDA-approved drugs","volume":"8","author":"Peng","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2021032314375369700_ref41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2011.05.006","article-title":"Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus","volume":"91","author":"\u00d6lschl\u00e4ger","year":"2011","journal-title":"Antiviral Res"},{"key":"2021032314375369700_ref42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","article-title":"The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide","volume":"147","author":"Tilmanis","year":"2017","journal-title":"Antiviral Res"},{"key":"2021032314375369700_ref43","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx009","article-title":"Pediatric drug nitazoxanide: a potential choice for control of Zika","volume":"4","author":"Cao","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021032314375369700_ref44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"2021032314375369700_ref45","doi-asserted-by":"crossref","DOI":"10.1186\/s43141-020-00055-5","article-title":"Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?","volume":"18","author":"Mahmoud","year":"2020","journal-title":"J Genet Eng Biotechnol"},{"key":"2021032314375369700_ref46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.antiviral.2016.10.003","article-title":"Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission","volume":"135","author":"Wang","year":"2016","journal-title":"Antiviral Res"},{"key":"2021032314375369700_ref47","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jmv.25031","article-title":"The antimalarial drug amodiaquine possesses anti-ZIKA virus activities","volume":"90","author":"Han","year":"2018","journal-title":"J Med Virol"},{"key":"2021032314375369700_ref48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PLoS One"},{"key":"2021032314375369700_ref49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2014.03.014","article-title":"Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity","volume":"106","author":"Boonyasuppayakorn","year":"2014","journal-title":"Antiviral Res"},{"key":"2021032314375369700_ref50","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3389\/fimmu.2019.00531","article-title":"Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy","volume":"10","author":"Pizzorno","year":"2019","journal-title":"Front Immunol"},{"key":"2021032314375369700_ref51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virusres.2019.02.011","article-title":"Drug repurposing for new, efficient, broad spectrum antivirals","volume":"264","author":"Garc\u00eda-Serradilla","year":"2019","journal-title":"Virus Res"},{"key":"2021032314375369700_ref52","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat Med"},{"key":"2021032314375369700_ref53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36636-1","article-title":"Drug repositioning for dengue haemorrhagic fever by integrating multiple omics analyses","volume":"9","author":"Amemiya","year":"2019","journal-title":"Sci Rep"},{"key":"2021032314375369700_ref54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A survey of current trends in computational drug repositioning","volume":"17","author":"Li","year":"2016","journal-title":"Brief Bioinform"},{"key":"2021032314375369700_ref55","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.ymthe.2019.10.006","article-title":"Suppression of Zika virus infection in the brain by the antiretroviral drug Rilpivirine","volume":"27","author":"Sariyer","year":"2019","journal-title":"Mol Ther"},{"key":"2021032314375369700_ref56","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of Zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"2021032314375369700_ref57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.14218\/JCTH.2018.00007","article-title":"Use of ribavirin for hepatitis C treatment in the modern direct-acting antiviral era","volume":"6","author":"Mathur","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"2021032314375369700_ref58","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2021032314375369700_ref59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2018.07.003","article-title":"Repurposing potential of 1st generation H-specific antihistamines as anti-filovirus therapeutics","volume":"157","author":"Schafer","year":"2018","journal-title":"Antiviral Res"},{"key":"2021032314375369700_ref60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fphar.2015.00171","article-title":"Adrenergic regulation of innate immunity: a review","volume":"6","author":"Scanzano","year":"2015","journal-title":"Front Pharmacol"},{"key":"2021032314375369700_ref61","doi-asserted-by":"crossref","first-page":"15137","DOI":"10.1074\/jbc.REV119.006901","article-title":"Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition","volume":"294","author":"Engelman","year":"2019","journal-title":"J Biol Chem"},{"key":"2021032314375369700_ref62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bib\/bbaa003","article-title":"Exploration of databases and methods supporting drug repurposing: a comprehensive survey","volume":"bbaa003","author":"Tanoli","year":"2020","journal-title":"Brief Bioinform"},{"key":"2021032314375369700_ref63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The drug repurposing hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat Med"},{"key":"2021032314375369700_ref64","first-page":"1","article-title":"Potential inhibitors for the novel coronavirus (SARS-CoV-2)","volume":"bbaa209","author":"Han","year":"2020","journal-title":"Brief Bioinform"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/2\/1076\/36653939\/bbaa421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/2\/1076\/36653939\/bbaa421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T14:17:03Z","timestamp":1670509023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/22\/2\/1076\/6105944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,22]]},"published-print":{"date-parts":[[2021,3,22]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaa421","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,1,22]]}}}